Cardiothoracic Sale Contemplated As Genzyme Ends Tracking Stock Strategy
This article was originally published in The Gray Sheet
Executive Summary
Genzyme Biosurgery plans to divest the bulk of its cardiothoracic devices business by year-end to focus on its orthopedics and biosurgical specialties units